Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

Shots:

  • Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based, multi-cancer screening test. The transaction is expected to be close in Q1’21
  • The acquisition will establish Exact Sciences as a leading competitor in blood-based, multi-cancer screening with the addition of Thrive’s, CancerSEEK. The agreement will accelerate the approval, availability, and adoption of multi-cancer screening
  • Additionally, Exact Sciences also acquires Base Genomics to extend its DNA methylation capabilities. The acquisition will boost Exact Sciences’ efforts in cancer diagnostics across the continuum

Click here ­to­ read full press release/ article | Ref: Exact Sciences | Image: European Coatings

The post Exact Sciences to Acquire Thrive Earlier Detection for ~.15B first appeared on PharmaShots.

Thrive raises $257M Series B round for registration study of blood test for early cancer detection

The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.